--- title: "Erasca (ERAS) news: class action and offering" url: "https://aibio.space/companies/erasca/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ERAS class action and offering news: Erasca faces securities class action and ERAS-0015 derivative suit. Erasca, Inc. (NASDAQ: ERAS), United States." --- ERAS Erasca, Inc. NASDAQ · United States # Erasca (ERAS) news ERAS class action and offering news Legal · 2026-08-11 ## [Erasca faces securities class action and ERAS-0015 derivative suit](https://aibio.space/news/erasca-faces-securities-class-action-eras-0015-derivative-suit/) Erasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action. ## Latest Erasca news 1. 2026-07-13 Financings [Erasca launches $500,000,000 stock offering, then prices 31,428,572 shares at $17.50](https://aibio.space/news/erasca-launches-500-000-000-stock-offering-then-prices-31-428-572/) Erasca's final terms are 31,428,572 shares at $17.50, a total of $550,000,010.00, above the $500,000,000 first announced. Its two clinical-stage programs are early, and the annual report shows a net loss of $124.5 million for 2025. ## Erasca at a glance - **Ticker**: ERAS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $268.7 million ### Related companies - [Aktis Oncology](https://aibio.space/companies/aktis-oncology/) NASDAQ: AKTS - [MabCure](https://aibio.space/companies/mabcure/) OTC: MBCI - [Ocugen](https://aibio.space/companies/ocugen/) NASDAQ: OCGN - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) NASDAQ: LTGO - [IDEAYA Biosciences](https://aibio.space/companies/ideaya-biosciences/) NASDAQ: IDYA - [Actinium Pharmaceuticals, Inc. (Delaware)](https://aibio.space/companies/actinium-pharmaceuticals-delaware/) AMEX: ATNM - [Trafalgar International](https://aibio.space/companies/trafalgar-international/) OTC: TRFA - [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) NASDAQ: ARTL ### Also on NASDAQ - [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) WHWK - [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) LUCD - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) CNXU - [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) OVID - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) ENVB - [Alpha Tau Medical](https://aibio.space/companies/alpha-tau-medical/) DRTS ## What Erasca does Erasca is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company says these alterations account for more than five million new cancer patients diagnosed globally each year. Its modality-agnostic pipeline pursues three strategies: targeting upstream and downstream MAPK pathway nodes, targeting RAS directly, and targeting escape routes that enable resistance. Its lead program, ERAS-0015, is a pan-RAS molecular glue licensed from Guangzhou Joyo Pharmatech, being tested in the AURORAS-1 Phase 1 trial, which the FDA cleared in May 2025, and in a Phase 1 trial in China sponsored by Joyo. In a January 2026 update, Erasca reported ongoing confirmed and unconfirmed responses, no dose-limiting toxicities and linear pharmacokinetics, and it had dosed patients at 40 mg once daily after a low dose of 8 mg once daily. Its second clinical program, ERAS-4001, is a potential first-in-class pan-KRAS inhibitor, and ERAS-12, an EGFR D2/D3 biparatopic antibody, is at discovery stage. | Product or program | What it is | Stage | |---|---|---| | ERAS-0015 | Pan-RAS molecular glue for RAS-mutated solid tumors | Phase 1 | | ERAS-4001 | Potential first-in-class pan-KRAS inhibitor for KRAS-mutated solid tumors | clinical-stage | | ERAS-12 | EGFR D2/D3 biparatopic antibody | discovery stage | Summarised from the company's [10-K filed Mar 12, 2026](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/eras-20251231.htm). ## Erasca annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$92.9 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | [$115.4 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | | Net income (loss) | [-$124.5 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | [-$161.7 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | | Cash from operations | [-$95.5 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | [-$109.4 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | | Cash and equivalents | [$73.8 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526344611/) | [$67.7 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | | Short-term investments | [$202.3 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526344611/) | [$230.6 million](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104150/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $42.5 million, plus short-term investments of $226.2 million, $268.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Erasca Is there a class action against Erasca? Our latest story on this, dated Aug 11, 2026: "Erasca faces securities class action and ERAS-0015 derivative suit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/erasca-faces-securities-class-action-eras-0015-derivative-suit/). Has Erasca raised money recently? Our latest story on this, dated Jul 13, 2026: "Erasca launches $500,000,000 stock offering, then prices 31,428,572 shares at $17.50". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/erasca-launches-500-000-000-stock-offering-then-prices-31-428-572/). What is the ticker symbol of Erasca? Erasca, Inc. trades under the ticker ERAS on NASDAQ. Where is Erasca listed? Erasca, Inc. is listed on NASDAQ. What is the SEC CIK of Erasca? The SEC Central Index Key (CIK) for Erasca, Inc. is 1761918. Its filings are on SEC EDGAR. How many shares does Erasca have outstanding? 349,762,035 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Erasca listed under? Our directory records Erasca, Inc. under United States. What does Erasca do? Our directory classifies Erasca, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Erasca? The ISIN recorded for Erasca, Inc. is US29479A1088. Does aibio.space cover Erasca? aibio.space lists Erasca, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Erasca incorporated? SEC records list its state or country of incorporation as DE. What does Erasca develop? Erasca is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company says these alterations account for more than five million new cancer patients diagnosed globally each year. What is ERAS-0015 from Erasca? ERAS-0015: Pan-RAS molecular glue for RAS-mutated solid tumors Stage: Phase 1. What is ERAS-4001 from Erasca? ERAS-4001: Potential first-in-class pan-KRAS inhibitor for KRAS-mutated solid tumors Stage: clinical-stage. Is Erasca profitable? Erasca, Inc. reported a net loss of $124.5 million for the fiscal year ended Dec 31, 2025, and used $95.5 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Erasca Members talk about Erasca (ERAS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Erasca, newest first. Each line links the filing it comes from. 1. 2026-08-11 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1761918/000119312526344611/eras-20260630.htm) 2. 2026-07-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1761918/000119312526302148/d116467d424b5.htm) 3. 2026-01-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1761918/000119312526016549/d63320d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ERAS on TradingView](https://www.tradingview.com/symbols/NASDAQ-ERAS/). ## SEC filings and registration - **SEC name**: Erasca, Inc. - **CIK**: 1761918 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ERAS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121 - **Phone**: (858) 465-6511 - **Shares outstanding**: 349,762,035 as of 2026-08-04 (10-Q filed 2026-08-11) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1761918/000119312526423433/eras-20261015.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1761918/000119312526361895/eras-20260824.htm) filed 2026-08-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1761918/000119312526344611/eras-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1761918/000119312526344584/eras-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1761918/000119312526342669/eras-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1761918/000119312526303357/d371010d8k.htm) filed 2026-07-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1761918/000119312526303352/d116467d424b5.htm) filed 2026-07-14 - [424B5](https://www.sec.gov/Archives/edgar/data/1761918/000119312526302148/d116467d424b5.htm) filed 2026-07-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001761918), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Erasca, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ERAS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Erasca, Inc. - **Ticker**: ERAS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US29479A1088 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ERAS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/erasca/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Erasca (ERAS) news: class action and offering", 2026-10-31, https://aibio.space/companies/erasca/